{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:01:40Z","timestamp":1782586900067,"version":"3.54.5"},"reference-count":70,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Despite the expansion of the understanding in asthma pathophysiology and the continual advances in disease management, a small subgroup of patients remains partially controlled or refractory to standard treatments. Upon the identification of immunoglobulin E (IgE) and other inflammatory mediators, investigations and developments of targeted agents have thrived. Omalizumab is a humanized monoclonal antibody that specifically targets the circulating IgE, which in turn impedes and reduces subsequent releases of the proinflammatory mediators. In the past decade, omalizumab has been proven to be efficacious and well-tolerated in the treatment of moderate-to-severe asthma in both trials and real-life studies, most notably in reducing exacerbation rates and corticosteroid use. While growing evidence has demonstrated that omalizumab may be potentially beneficial in treating other allergic diseases, its indication remains confined to treating severe allergic asthma and chronic idiopathic urticaria. Future efforts may be bestowed on determining the optimal length of omalizumab treatment, seeking biomarkers that could better predict treatment response and as well as extending its indications.<\/jats:p>","DOI":"10.3390\/diagnostics11010083","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T20:45:42Z","timestamp":1609965942000},"page":"83","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immunologic Pathophysiology and Airway Remodeling Mechanism in Severe Asthma: Focused on IgE-Mediated Pathways"],"prefix":"10.3390","volume":"11","author":[{"given":"Shih-Lung","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Far Eastern Memorial Taipei Hospital, Department of Chemical Engineering and Materials Science, Yuan Ze University, Zhongli, Taoyuan 32056, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(17)30879-6","article-title":"After asthma: Redefining airways diseases","volume":"391","author":"Pavord","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4137\/CCRPM.S5535","article-title":"Optimal Management of Severe\/Refractory Asthma","volume":"5","author":"Pakhale","year":"2011","journal-title":"Clin. Med. Insights Circ. Respir. Pulm. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2006.09.045","article-title":"Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma","volume":"119","author":"Takhar","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.blre.2010.06.002","article-title":"Understanding the genetic regulation of IgE production","volume":"24","author":"Altin","year":"2010","journal-title":"Blood Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1183\/13993003.01824-2014","article-title":"Asthma phenotypes and IgE responses","volume":"47","author":"Froidure","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1164\/rccm.200209-1030OC","article-title":"Airway Structural Alterations Selectively Associated with Severe Asthma","volume":"167","author":"Benayoun","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1378\/chest.112.1.45","article-title":"Bronchial Subepithelial Fibrosis Correlates With Airway Responsiveness to Methacholine","volume":"112","author":"Boulet","year":"1997","journal-title":"Chest"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1183\/09059180.00004413","article-title":"Tissue remodeling in chronic bronchial disease: From the epithelial to mesenchymal phenotype","volume":"23","author":"Pain","year":"2014","journal-title":"Eur. Respir. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(06)69288-X","article-title":"The mechanisms, diagnosis, and management of severe asthma in adults","volume":"368","author":"Holgate","year":"2006","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/02770900601031540","article-title":"High Prevalence of Skin Test Positivity in Severe or Difficult-to-Treat Asthma","volume":"43","author":"Haselkorn","year":"2006","journal-title":"J. Asthma"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2006.11.639","article-title":"Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute\u2019s Severe Asthma Research Program","volume":"119","author":"Moore","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_12","unstructured":"(2003). The ENFUMOSA Study Group. Eur. Respir. J., 22, 470\u2013477."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fimmu.2012.00229","article-title":"Cytokinergic IgE Action in Mast Cell Activation","volume":"3","author":"Bax","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri2273","article-title":"IgE in allergy and asthma today","volume":"8","author":"Gould","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fimmu.2014.00234","article-title":"Immune responses to inhalant mammalian allergens","volume":"5","author":"Hentges","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jaci.2011.10.029","article-title":"The who, where, and when of IgE in allergic airway disease","volume":"129","author":"Dullaers","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_17","first-page":"447","article-title":"Moving toward consensus on diagnosis and management of severe asthma in children","volume":"34","author":"Nieto","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1165\/ajrcmb.19.1.2648","article-title":"Expression of the High-affinity Receptor for IgE on Bronchial Epithelial Cells of Asthmatics","volume":"19","author":"Campbell","year":"1998","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.4049\/jimmunol.1800709","article-title":"Bronchial Allergen Challenge of Patients with Atopic Asthma Triggers an Alarmin (IL-33, TSLP, and IL-25) Response in the Airways Epithelium and Submucosa","volume":"201","author":"Wang","year":"2018","journal-title":"J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.4049\/jimmunol.175.4.2613","article-title":"Human Airway Smooth Muscle Cells Express the High Affinity Receptor for IgE (Fc\u03b5RI): A Critical Role of Fc\u03b5RI in Human Airway Smooth Muscle Cell Function","volume":"175","author":"Gounni","year":"2005","journal-title":"J. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pupt.2012.04.004","article-title":"The high affinity IgE receptor (Fc\u03b5RI) expression and function in airway smooth muscle","volume":"26","author":"Redhu","year":"2013","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Roth, M., Zhong, J., Zumkeller, C., S\u2019ng, C.T., Goulet, S., and Tamm, M. (2013). The role of IgE-receptors in IgE-dependent airway smooth muscle cell remodeling. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056015"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Roth, M., Zhao, F., Zhong, J., Lardinois, D., and Tamm, M. (2015). Serum IgE Induced Airway Smooth Muscle Cell Remodeling Is Independent of Allergens and Is Prevented by Omalizumab. PLOS ONE, 10.","DOI":"10.1371\/journal.pone.0136549"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.it.2008.07.004","article-title":"The multiple roles of phosphoinositide 3-kinase in mast cell biology","volume":"29","author":"Kim","year":"2008","journal-title":"Trends Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Fang, L., Wang, X., Sun, Q., Papakonstantinou, E., S\u2019Ng, C., Tamm, M., Stolz, D., and Roth, M. (2019). IgE Downregulates PTEN through MicroRNA-21-5p and Stimulates Airway Smooth Muscle Cell Remodeling. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040875"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pelaia, G., Vatrella, A., and Maselli, R. (2016). Anti-IgE Therapy. Asthma: Targeted Biological Therapies, Springer Science and Business Media LLC.","DOI":"10.1007\/978-3-319-46007-9"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3389\/fimmu.2020.01134","article-title":"Biological Therapies of Severe Asthma and Their Possible Effects on Airway Remodeling","volume":"11","author":"Kardas","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/039463201202500217","article-title":"Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients","volume":"25","author":"Riccio","year":"2012","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1159\/000334701","article-title":"Effects of Adding Omalizumab, an Anti-Immunoglobulin E Antibody, on Airway Wall Thickening in Asthma","volume":"83","author":"Hoshino","year":"2012","journal-title":"Respir"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.imlet.2014.08.010","article-title":"Proteomics of bronchial biopsies: Galactin-3 as a predictive biomarker of airway remodeling modulation in Omalizumab-treated severe asthma patients","volume":"162","author":"Mauri","year":"2014","journal-title":"Immunol. Lett."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.anai.2014.06.004","article-title":"Comprehensive efficacy of omalizumab for severe refractory asthma: A time-series observational study","volume":"113","author":"Tajiri","year":"2014","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13601-017-0143-1","article-title":"Galectin-3: An early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months","volume":"7","author":"Riccio","year":"2017","journal-title":"Clin. Transl. Allergy"},{"key":"ref_33","first-page":"468","article-title":"Omalizumab may decrease the thickness of the reticular basement membrane and fibronectin deposit in the bronchial mucosa of severe allergic asthmatics","volume":"57","author":"Przybyszowski","year":"2019","journal-title":"J. Asthma"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.rmed.2009.09.011","article-title":"Effect of omalizumab on peripheral blood eosinophilia in allergic asthma","volume":"104","author":"Massanari","year":"2010","journal-title":"Respir. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000317137","article-title":"Anti-IgE therapy with Omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma","volume":"80","author":"Zietkowski","year":"2010","journal-title":"Respiration"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma","volume":"170","author":"Djukanovic","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cea.13248","article-title":"Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy","volume":"49","author":"Huang","year":"2019","journal-title":"Clin. Exp. Allergy"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1081-1206(10)61170-2","article-title":"Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells","volume":"95","author":"Huang","year":"2005","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ejcdt.2015.07.002","article-title":"Study of the effect of anti-IgE (Omalizumab) on serum level of matrix metalloproteinase-9 as a marker of remodeling in severe asthmatic patients","volume":"64","author":"Affara","year":"2015","journal-title":"Egypt J. Chest Dis. Tuberc."},{"key":"ref_40","first-page":"CD003559","article-title":"Omalizumab for asthma in adults and children","volume":"1","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jaip.2017.02.002","article-title":"\u201cReal-life\u201d Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis","volume":"5","author":"Lee","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/1744666X.2019.1574571","article-title":"Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: Systematic review of 42 studies published 2008-2018","volume":"15","author":"Macdonald","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Busse, W.W., Szefler, S.J., Haselkorn, T., Iqbal, A., Ortiz, B., Lanier, B.Q., and Chipps, B.E. (2020). Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations. J. Allergy Clin. Immunol. Pract.","DOI":"10.1016\/j.jaip.2020.10.027"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.anai.2009.11.022","article-title":"The effects of Omalizumab on IgE-induced cytokine synthesis by asthmatic airway smooth muscle cells","volume":"104","author":"Roth","year":"2010","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1183\/09031936.00019906","article-title":"Tools used to measure airway remodelling in research","volume":"29","author":"Bergeron","year":"2007","journal-title":"Eur. Respir. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jaci.2005.06.011","article-title":"Differences in airway remodeling between subjects with severe and moderate asthma","volume":"116","author":"Pepe","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1164\/rccm.200410-1404OC","article-title":"Airway remodeling and inflammation in symptomatic infants with re-versible airflow obstruction","volume":"171","author":"Saglani","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1164\/rccm.200202-150WS","article-title":"Methods for the assessment of endobronchial biopsies in clinical research: Application to studies of pathogenesis and the effects of treatment","volume":"168","author":"Jeffery","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40248-019-0176-5","article-title":"Does transbronchial lung cryobiopsy give useful information in asthmatic patients?","volume":"14","author":"Colella","year":"2019","journal-title":"Multidiscip. Respir. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1378\/chest.127.6.1919","article-title":"A Comparison of Airway and Serum Matrix Metalloproteinase-9 Activity Among Normal Subjects, Asthmatic Patients, and Patients With Asthmatic Mucus Hypersecretion","volume":"127","author":"Ko","year":"2005","journal-title":"Chest"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1034\/j.1600-0463.2002.1101102.x","article-title":"Soluble membrane-type 1 matrix metalloproteinase (MT1-MMP) and gelatinase A (MMP-2) in induced sputum and bronchoalveolar lavage fluid of human bronchial asthma and bronchiectasis","volume":"110","author":"Maisi","year":"2002","journal-title":"APMIS"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1081\/JAS-100105868","article-title":"Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in sputum from patients with bronchial asthma","volume":"38","author":"Suzuki","year":"2001","journal-title":"J. Asthma"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1164\/ajrccm.158.6.9803014","article-title":"Sputum Metalloproteinase-9\/Tissue Inhibitor of Metalloproteinase-1 Ratio Correlates with Airflow Obstruction in Asthma and Chronic Bronchitis","volume":"158","author":"Vignola","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1378\/chest.122.5.1543","article-title":"Matrix metalloproteinase-9 expression in asthma: Effect of asthma severity, allergen challenge, and inhaled corticosteroids","volume":"122","author":"Jatakanon","year":"2002","journal-title":"Chest"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cccn.2005.01.012","article-title":"Exhaled breath condensate analysis in patients with COPD","volume":"356","author":"Montuschi","year":"2005","journal-title":"Clin. Chim. Acta"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1183\/09031936.05.00029705","article-title":"Exhaled breath condensate: Methodological recommendations and unresolved questions","volume":"26","author":"Horvath","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2222.2002.01219.x","article-title":"Increased release of matric metalloproteinase-9 in the plasma of acute severe asthmatic patients","volume":"32","author":"Belleguic","year":"2002","journal-title":"Clin. Exp. Allergy"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1046\/j.1365-2222.2001.01034.x","article-title":"Serum eosinophil cationic protein levels measured during exacerbation of asthma: Characteristics of patients with low titres","volume":"31","author":"Matsumoto","year":"2001","journal-title":"Clin. Exp. Allergy"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1399-3038.2006.00387.x","article-title":"Increased glycosaminoglycans in the urine of asthmatic children on inhaled corticosteroids","volume":"17","author":"Priftis","year":"2006","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2214\/ajr.179.5.1791245","article-title":"Thoracic CT in Pediatric Patients with Difficult-to-Treat Asthma","volume":"179","author":"Marchac","year":"2002","journal-title":"Am. J. Roentgenol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200410-1311OC","article-title":"Changes in airway dimensions on computed tomography scans of children with cystic fibrosis","volume":"172","author":"Nakano","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2016.11.009","article-title":"Using imaging as a biomarker for asthma","volume":"139","author":"Trivedi","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1164\/rccm.200712-1776OC","article-title":"Airway wall thickness assessed using computed tomography and optical coherence tomography","volume":"177","author":"Coxson","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1164\/rccm.201002-0178OC","article-title":"Elastics properties of the central airways in obstructive lung diseases measured using anatomical optical coherence tomography","volume":"183","author":"Williamson","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Bullone, M., Beauchamp, G., Godbout, M., Martin, J.G., and Lavoie, J.-P. (2015). Endobronchial ultrasound reliably quantifies airway smooth muscle remodeling in an equine asthma model. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136284"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1164\/ajrccm.164.9.2102039","article-title":"Reduced Airway Distensibility, Fixed Airflow Limitation, and Airway Wall Remodeling in Asthma","volume":"164","author":"Ward","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3132\/pcrj.2008.00031","article-title":"The use of Omalziumab in asthma","volume":"17","author":"Price","year":"2008","journal-title":"Prim. Care Respir. J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.201701-0120OC","article-title":"Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma","volume":"196","author":"Esquivel","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Criado, P.R., Pagliari, C., Criado, R.F.J., Marques, G.F., and Belda, W. (2020). What the physicians should know about mast cells, dendritic cells, urticaria, and Omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2?. Dermatol. Ther., e14068.","DOI":"10.1111\/dth.14068"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/1\/83\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:07:49Z","timestamp":1760159269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/1\/83"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["diagnostics11010083"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics11010083","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]}}}